Bloomberg reports that Illumina (ILMN -4.2%) is in advanced talks to acquire Grail (GRAL), a spinout that it formed in 2015 to develop and commercialize liquid biopsy testing for cancer.
According to informed sources, a deal could be announced as soon as this week. Grail could fetch more than $6B based on its valuation from the last financing round.
A week ago, Grail filed a preliminary prospectus for an IPO.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.